SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon stock faces continued downward pressure as the community discusses concerns over heavy capital expenditure for AI infrastructure and potential data losses at Middle Eastern facilities, while traders debate the impact of broader market headwinds like rising yields and Fed rate expectations.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded by Keyvan Mohajer, Majid Seyed Emami and James M. Hom on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is receiving significant attention following the completion of its acquisition of LivePerson, which traders are debating as either a strategic move to boost enterprise scale and profitability or a risky gamble due to integration concerns and share dilution. While some investors view the current price weakness as a buying opportunity given the potential for a short squeeze and long-term growth, others remain skeptical, citing persistent downward price action, management criticism, and concerns over the company's path to profitability.

Forgent Power Solutions, Inc. is a holding company, which engages in the design and manufacture of electrical distribution equipment used in data centers, power grid, and energy-intensive industrial facilities. It also offers powertrain solutions and standard and custom products. The company was founded on July 21, 2025 and is headquartered in Dayton, MN.

Forgent Power Solutions Inc. - Ordinary Shares - Class A

Forgent Power Solutions Inc.

Forgent Power Solutions is trending after reporting record fourth-quarter results and fiscal 2027 guidance that exceeded analyst expectations, driven by a surge in backlog orders. While the company faces pressure from ongoing profit-taking and volatility, sentiment remains highly bullish due to strong fundamentals in the power infrastructure and data center sectors.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is trending as traders speculate on positive guidance updates and imminent Phase 2 NSCLC trial data following the company's recent healthcare conference presentations. Investors are expressing confidence in the company's commercial growth, clinical pipeline, and management's stated progress toward profitability.

Starbucks Corp. engages in the production, marketing, and retailing of specialty coffee. It operates through the following segments: North America, International, and Channel Development. The North America segment focuses on the United States and Canada. The International segment is involved in China, Japan, Asia Pacific, Europe, Middle East, Africa, Latin America, and Caribbean. The Channel Development segment includes roasted whole bean and ground coffees, Seattle’s Best Coffee, and Teavana-branded single-serve products. The company was founded by Jerry Baldwin and Howard D. Schultz on November 4, 1985, and is headquartered in Seattle, WA.

Starbucks Corp.

Starbucks Corp

Starbucks is trending as investors weigh mixed signals regarding its turnaround efforts, with some focusing on reports of rising afternoon traffic and a potential stake sale in its Japan business, while others express skepticism over valuation and the competitive landscape.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SPCX is seeing significant volatility as traders react to upcoming Starship orbital flight tests and broader market uncertainty surrounding a potential Fed interest rate hike. Investors remain divided, with many debating the impact of upcoming Nasdaq rebalancing and future revenue potential against concerns over share dilution and high valuations.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending as traders speculate on potential acquisition interest from a mid-to-large cap biopharma, though market participants remain divided on the validity of these reports. Long-term investors are focused on the commercial growth of Briumvi and upcoming data catalysts, suggesting the stock remains a strong prospect even without an immediate buyout.

McDonald's Corp. engages in the operation and franchising of restaurants. The firm operates through the following segments: U.S., International Operated Markets, and International Developmental Licensed Markets and Corporate. The U.S. segment focuses its operations on the United States. The International Operated Markets segment consists of operations and the franchising of restaurants in Australia, Canada, France, Germany, Italy, the Netherlands, Russia, Spain, and the U.K. The International Developmental Licensed Markets and Corporate segment consists of developmental licensee and affiliate markets in the McDonald’s system. Its products include Big Mac, Quarter Pounder with Cheese, Filet-O-Fish, several chicken sandwiches, Chicken McNuggets, wraps, McDonald's Fries, salads, oatmeal, shakes, McFlurry desserts, sundaes, soft serve cones, pies, soft drinks, coffee, and McCafe beverages. The company was founded by Raymond Albert Kroc on April 15, 1955 and is headquartered in Chicago, IL.

McDonald`s Corp

McDonald's Corp

McDonald's is facing intense selling pressure as traders debate its status as a defensive blue chip in a challenging consumer environment, with many pointing to the stock hitting new 52-week lows. While some investors view the current valuation as a generational buying opportunity due to the company's real estate holdings and dividend, others remain bearish, citing concerns over restaurant traffic, pricing power, and broader economic headwinds.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is facing community scrutiny following the announcement that CFO Claire McDonough is stepping down to join GE Vernova, a transition that has triggered debate regarding company leadership and execution risk. While some investors view the departure as a negative signal for the R2 production ramp, others interpret it as an opportunity for new leadership to improve shareholder value.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Cipher Digital is trending following reports that the company received conditional grid capacity classifications from ERCOT for a significant portion of its pipeline, fueling optimism about its transition into an AI power infrastructure provider. While the news sparked momentum, sentiment remains divided as traders debate the scale of the approval versus market expectations and monitor broader macro-economic factors surrounding data center investments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Part 2
$EYPT What if the market has identified the wrong Phase 3 risk?

SOL-R is the trial that asks whether q6M AXPAXLI can actually preserve mean vision comparably to on-label q8w aflibercept using the same −4.5-letter NI margin that challenged LUGANO.

So here is the real “what if”:

What if LUCIA validates DURAVYU… and SOL-R later fails to prove AXPAXLI noninferior to standard-of-care Eylea?

Then the irony would be extraordinary.

The market may have punished DURAVYU for a statistical anomaly while assuming its competitor had already proven superiority—when in fact the competitor’s most demanding Phase 3 test was still ahead.

And DURAVYU may not even need to replace Eylea, Vabysmo or Eylea HD. EyePoint is positioning it as foundational long-duration therapy, with biologics layered in when needed.

What if the real competitive risk was never DURAVYU vs AXPAXLI?

What if it was which program could actually survive the full-strength Eylea comparison?

Ivor Driver

guido rizzato

B Holder

StockTwits for iOS

EyePoint Pharmaceuticals Inc

 What if the market has identified the wrong Phase 3 risk?

SOL-R is the trial that asks whether q6M AXPAXLI can actually preserve mean vision comparably to on-label q8w aflibercept using the same −4.5-letter NI margin that challenged LUGANO.

So here is the real “what if”:

What if LUCIA validates DURAVYU… and SOL-R later fails to prove AXPAXLI noninferior to standard-of-care Eylea?

Then the irony would be extraordinary.

The market may have punished DURAVYU for a statistical anomaly while assuming its competitor had already proven superiority—when in fact the competitor’s most demanding Phase 3 test was still ahead.

And DURAVYU may not even need to replace Eylea, Vabysmo or Eylea HD. EyePoint is positioning it as foundational long-duration therapy, with biologics layered in when needed.

What if the real competitive risk was never DURAVYU vs AXPAXLI?

What if it was which program could actually survive the full-strength Eylea comparison?

Jim Dierking

@Jdliberty   You do not understand the SOL-1 results or the SOL-R design.  You are also not going to see SOL-R results for a long time given the modified prodigal.  

$OCUL has much better studies and data than $EYPT.   They have  2/3 of patients going a full year on one injection.   The stat significance is awesome with values like p&lt;.0001.   

If you listen to $EYPT PR without taking a close look at the numbers, you get it really wrong.

kyle

Ocular Therapeutix Inc

   You do not understand the SOL-1 results or the SOL-R design.  You are also not going to see SOL-R results for a long time given the modified prodigal.  



.   They have  2/3 of patients going a full year on one injection.   The stat significance is awesome with values like p<.0001.   

If you listen to 

 PR without taking a close look at the numbers, you get it really wrong.